Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... DUBLIN , May 20, 2015 Research and ... addition of the "Top Technologies in HW_Technical Insights" ... division of this report evaluated technology trends in the ... trends that are likely to have an impact in ... depth analysis of the top 10 health and wellness ...
(Date:5/20/2015)... The global genotyping market is expected ... forecast period of 2015 to 2020 to reach $17.0billion ... drug discovery and development process and to provide personalized ... to this,heavy investments by key manufacturers to offer advanced ... market growth. Browse 113 market data tables & 37 ...
(Date:5/20/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at The Jefferies 2015 Global Healthcare Conference in ... st , 2015 at 8:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jeff88/hae ... is a global healthcare company dedicated to providing innovative ...
(Date:5/20/2015)... PARK, North Carolina , 20. ... führende Unternehmen für klinische Logistik (Clinical ... für das Geschäftsjahr 2014, das am ... eingereicht. Das Unternehmen hat die Marktentwicklung ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
Breaking Biology Technology:Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2
... Quanterix Corporation, a company enabling a new generation of ... ngle Mo lecule A rray (SiMoA ™ ... of its Prostate Specific Antigen (PSA) test, a fifth-generation ... predictor of five-year biochemical recurrence (BCR)-free survival following radical ...
... to make a highly efficient and yet cheaper silicon ... the cost of solar energy can be halved. ... Institute of Microelectronics (IME), the new thin-film silicon solar ... grade silicon. However it is able to generate electricity ...
... deCODE genetics today ... with Pfizer Inc., the objective of which is to ... to Systemic Lupus Erythematosis by utilizing deCODE,s expertise in ... extensive population and genetic resources, including DNA samples and ...
Cached Biology Technology:Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery 2Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery 3NTU and A*STAR Institute of Microelectronics develop cheaper yet efficient thin film solar cells 2deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis 2
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly advancing, ... and in the cloud. Passwords and their management are ... OTP and standards-based specifications such as those developed by ... use of passwords presents for BYOD, COPE, IoT, and ... biometric identity protocol. In response to ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... 28, 2009, Drinking cherry juice could help ease the ... Oregon Health & Science University presented at the American College ... showed people who drank tart cherry juice while training for ... than those who didn,t. Post-exercise pain can often indicate ...
... both milk feeding and in the weaning diet are ... have independent influences on body composition in early childhood, ... The Endocrine Society,s Journal of Clinical Endocrinology & ... suggest that the early environment may be a significant ...
... to alleviate diseases associated with menopause, she didn,t realize ... feeding hundreds of millions of people. The Northern ... the University of Arizona identified a nontoxic chemical technology ... which feast on crops intended for human consumption. ...
Cached Biology News:Is cherry juice a new 'sports drink?' 2Breastfeeding duration and weaning diet may shape child's body composition 2NAU discovery could help feed millions 2NAU discovery could help feed millions 3
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in cell ... Purity: ≥98% by TLC. Soluble in DMSO ... of a 10 mM stock in DMSO is recommended. ... H 2 O with rapid mixing (e.g. 10 μl ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: